Kura Oncology Inc (KURA) — Cash Flow-to-Debt Ratio
Kura Oncology Inc (KURA) has a Cash Flow-to-Debt Ratio of 0.21x as of December 2025, meaning its operating cash flow of $117.27 Million could theoretically repay 0% of its total liabilities ($564.23 Million) in one year. See Kura Oncology Inc free cash flow generation to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Kura Oncology Inc Cash Flow-to-Debt Ratio (2009–2025)
Historical debt coverage capacity for Kura Oncology Inc across 17 annual periods. Also explore KURA net asset momentum to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Kura Oncology Inc (2009–2025)
Year-by-year debt coverage analysis for Kura Oncology Inc. For market capitalisation and broader financial context, see Kura Oncology Inc stock valuation.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.11x | $-64.06 Million | $564.23 Million | ▼ -129.3% |
| 2024 | 0.39x | $134.32 Million | $346.52 Million | ▲ +116.0% |
| 2023 | -2.42x | $-124.82 Million | $51.66 Million | ▲ +20.9% |
| 2022 | -3.05x | $-110.06 Million | $36.03 Million | ▲ +19.8% |
| 2021 | -3.81x | $-104.55 Million | $27.44 Million | ▼ -98.1% |
| 2020 | -1.92x | $-69.83 Million | $36.31 Million | ▲ +18.5% |
| 2019 | -2.36x | $-54.76 Million | $23.19 Million | ▼ -3.8% |
| 2018 | -2.27x | $-48.66 Million | $21.39 Million | ▼ -27.8% |
| 2017 | -1.78x | $-28.44 Million | $15.99 Million | ▲ +9.1% |
| 2016 | -1.96x | $-25.35 Million | $12.95 Million | ▲ +43.7% |
| 2015 | -3.48x | $-17.93 Million | $5.16 Million | ▼ -656578.3% |
| 2014 | 0.00x | $-2.55K | $4.81 Million | ▲ +99.7% |
| 2013 | -0.18x | $-24.42K | $133.03K | ▲ +16.1% |
| 2012 | -0.22x | $-22.68K | $103.65K | ▲ +15.0% |
| 2011 | -0.26x | $-19.24K | $74.75K | ▲ +5.8% |
| 2010 | -0.27x | $-19.24K | $70.39K | ▲ +59.5% |
| 2009 | -0.68x | $-21.37K | $31.61K | — |